Show simple item record

AuthorAl-Sadeq, Duaa W
AuthorShurrab, Farah M
AuthorIsmail, Ahmed
AuthorAmanullah, Fathima Humaira
AuthorThomas, Swapna
AuthorAldewik, Nader
AuthorYassine, Hadi M
AuthorAbdul Rahim, Hanan F
AuthorAbu-Raddad, Laith
AuthorNasrallah, Gheyath K
Available date2022-01-16T09:23:22Z
Publication Date2021-12-29
Publication NameJournal of Travel Medicine
Identifierhttp://dx.doi.org/10.1093/jtm/taab190
CitationDuaa W Al-Sadeq, MSc, Farah M Shurrab, BSc, Ahmed Ismail, MD, PhD, Fathima Humaira Amanullah, BSc, Swapna Thomas, MSc, Nader Aldewik, PhD, Hadi M Yassine, PhD, Hanan F Abdul Rahim, PhD, Laith Abu-Raddad, PhD, Gheyath K Nasrallah, PhD, Comparison of antibody immune responses between BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines in naïve and previously infected individuals, Journal of Travel Medicine, Volume 28, Issue 8, December 2021, taab190, https://doi.org/10.1093/jtm/taab190
URIhttp://hdl.handle.net/10576/25665
AbstractTwo mRNA vaccines, Pfizer-BNT162b2 and Moderna-mRNA-1273, obtained the Emergency Use Listing by WHO for preventing COVID-19. However, little is known about the difference in antibody responses induced by these two mRNA vaccines in naïve and previously infected (PI) individuals. We investigated the levels of anti-S-RBD (total, IgG and IgA) levels in naïve and PI individuals, 1-13 (median = 6) weeks following the second dose of either vaccine. Results in the naïve-vaccinated group, the mRNA-1273 vaccine induced significantly higher levels of anti-S-RBD total antibodies (3.5-fold; P < 0.001), IgG (2-fold, P < 0.01) and IgA (2.1-fold, P < 0.001) as compared with the BNT162b2 vaccine. In addition, both vaccines produced significantly higher anti-S-RBD total antibody levels in the PI-group compared with naïve-vaccinated group. The PI group elicited a higher level of anti-S-RBD IgG than the naïve-BNT162b2 (P = 0.05), but not more than the naïve-mRNA-1273 (P = 0.9) group. Interestingly, the PI vaccinated group elicited a comparable level of IgA ratio to the naïve-mRNA-1273 group but significantly higher than the naïve-BNT162b2 group (1.6-fold, P < 0.001). Our results showed that the PI-vaccinated group produces a higher level of antibodies than the naïve vaccinated group, particularly for those vaccinated with BNT162b2.
Languageen
PublisherOxford University Press
SubjectModerna-mRNA-1273
Pfizer-BNT162b2
S-RBD IgA
S-RBD IgG
immune response
TitleComparison of antibody immune responses between BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines in naïve and previously infected individuals.
TypeArticle
Issue Number8
Volume Number28


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record